NCT02741947View on ClinicalTrials.gov

Levodopa Benserazide Generic Formulation Versus the Originator

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Parkinson Disease
Interventions
DRUG

Levodopa Benserazide Madopar

Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks

DRUG

Levodopa Benserazide Teva Italia

Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks

Trial Locations (1)

00163

Irccs San Raffaele Pisana, Rome

All Listed Sponsors
collaborator

Agenzia Italiana del Farmaco

OTHER_GOV

lead

IRCCS San Raffaele Roma

OTHER

NCT02741947 - Levodopa Benserazide Generic Formulation Versus the Originator | Biotech Hunter | Biotech Hunter